Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8205 + saruparib + rilvegostomig
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination investigational oncology regimen composed of **AZD8205**, **saruparib**, and **rilvegostomig**. AZD8205 is an experimental agent; saruparib is a selective small molecule inhibitor of Poly(ADP-ribose) polymerase (PARP), designed to disrupt DNA damage repair in tumor cells; and rilvegostomig (also known as AZD2936) is a bispecific monoclonal antibody targeting both **TIGIT** and **PD-1** checkpoint proteins, aiming to enhance anti-tumor immunity. The regimen is being studied in advanced cancers, with each agent contributing a distinct mechanism: DNA repair inhibition (saruparib), dual immune checkpoint blockade (rilvegostomig), and additional undisclosed mechanisms from AZD8205. All three drugs are being developed by AstraZeneca for combination immunotherapy and chemotherapy approaches in cancers, especially lung and gastrointestinal malignancies[1][2][3][4][5][6].
- Other names
- AZD8205AZD-8205AZD 8205saruparibrilvegostomigAZD2936AZD-2936AZD 2936
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VTCN1 (V-set domain containing T cell activation inhibitor 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)TOP1 (DNA Topoisomerase I)PARP (PARP family)
Beyond the preview
Go deeper on AZD8205 + saruparib + rilvegostomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8205 + saruparib + rilvegostomig.